{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:12:08Z","timestamp":1782907928654,"version":"3.54.5"},"reference-count":213,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Non-Hodgkin lymphoma (NHL) is a broad entity which comprises a number of different types of lymphomatous malignancies. In the pediatric and adolescent population, the type and prognosis of NHL varies by age and gender. In comparison to adults, pediatric and adolescent patients generally have better outcomes following treatment for primary NHL. However, relapsed\/refractory (R\/R) disease is associated with poorer outcomes in many types of NHL such as diffuse large B cell lymphoma and Burkitt lymphoma. Newer therapies have been approved in the use of primary NHL in the pediatric and adolescent population such as Rituximab and other therapies such as chimeric antigen receptor T-cell (CAR T-cell) therapy are under investigation for the treatment of R\/R NHL. In this review, we feature the characteristics, diagnosis, and treatments of the most common NHLs in the pediatric and adolescent population and also highlight the differences that exist between pediatric and adult disease. We then detail the areas of treatment advances such as immunotherapy with CAR T-cells, brentuximab vedotin, and blinatumomab as well as cell cycle inhibitors and describe areas where further research is needed. The aim of this review is to juxtapose established research regarding pediatric and adolescent NHL with recent advancements as well as highlight treatment gaps where more investigation is needed.<\/jats:p>","DOI":"10.3390\/cancers14122912","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T22:00:38Z","timestamp":1655157638000},"page":"2912","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4869-8818","authenticated-orcid":false,"given":"Irtiza N.","family":"Sheikh","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Pediatric Hematology Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7970-7516","authenticated-orcid":false,"given":"Amr","family":"Elgehiny","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, McGovern Medical School, The University of Texas at Houston Health Science Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8199-9404","authenticated-orcid":false,"given":"Dristhi","family":"Ragoonanan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, CARTOX Program, Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris M.","family":"Mahadeo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, CARTOX Program, Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3731-608X","authenticated-orcid":false,"given":"Sajad","family":"Khazal","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, CARTOX Program, Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_2","first-page":"k3204","article-title":"Non-Hodgkin lymphoma","volume":"362","author":"Ajithkumar","year":"2018","journal-title":"BMJ"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1182\/asheducation-2007.1.297","article-title":"Should Adolescents with NHL Be Treated as Old Children or Young Adults?","volume":"2007","author":"Sandlund","year":"2007","journal-title":"Hematology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/pbc.21835","article-title":"Potential chemotherapy side effects: What do oncologists tell parents?","volume":"52","author":"Ramirez","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3324\/haematol.2019.238675","article-title":"Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas","volume":"106","author":"Svoboda","year":"2021","journal-title":"Haematologica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/asheducation-2016.1.589","article-title":"Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum","volume":"2016","author":"Sandlund","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Prog."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1182\/blood-2018-02-778480","article-title":"Management of aggressive B-cell NHLs in the AYA population: An adult vs pediatric perspective","volume":"132","author":"Dunleavy","year":"2018","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1182\/blood-2010-12-283093","article-title":"Malignant hematologic diseases in adolescents and young adults","volume":"117","author":"Wood","year":"2011","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1002\/cncr.23866","article-title":"Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975\u20131999","volume":"113","author":"Linabery","year":"2008","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/archpediatrics.2010.4","article-title":"Differences in Non-Hodgkin Lymphoma Survival between Young Adults and Children","volume":"164","author":"Tai","year":"2010","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/leu.2010.245","article-title":"Non-Hodgkin\u2019s lymphoma in adolescents: Experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols","volume":"25","author":"Burkhardt","year":"2011","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1200\/JCO.2000.18.21.3707","article-title":"Molecular biology of Burkitt\u2019s lymphoma","volume":"18","author":"Hecht","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S0140-6736(11)61177-X","article-title":"Burkitt\u2019s lymphoma","volume":"379","author":"Molyneux","year":"2012","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"a014282","DOI":"10.1101\/cshperspect.a014282","article-title":"Oncogenic mechanisms in Burkitt lymphoma","volume":"4","author":"Schmitz","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5595","DOI":"10.1038\/sj.onc.1204595","article-title":"Translocations involving c-myc and c-myc function","volume":"20","author":"Boxer","year":"2001","journal-title":"Oncogene"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0140-6736(95)11033-X","article-title":"HIV infection and neoplasia","volume":"348","author":"Schulz","year":"1996","journal-title":"Lancet"},{"key":"ref_17","unstructured":"Graham, B.S., and Lynch, D.T. (2021). Burkitt Lymphoma. StatPearls, StatPearls Publishing."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","article-title":"Virus Particles in Cultured Lymphoblasts from Burkitt\u2019s Lymphoma","volume":"1","author":"Epstein","year":"1964","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1084\/jem.121.5.761","article-title":"Morphological and Biological Studies on a Virus in Cultured Lymphoblasts from Burkitt\u2019s Lymphoma","volume":"121","author":"Epstein","year":"1965","journal-title":"J. Exp. Med."},{"key":"ref_20","first-page":"1397","article-title":"Epstein-Barr virus and Burkitt lymphoma","volume":"60","author":"Brady","year":"2007","journal-title":"J. Clin. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1179\/146532805X58120","article-title":"Burkitt lymphoma in Papua New Guinea\u201440 Years on","volume":"25","author":"Lavu","year":"2005","journal-title":"Ann. Trop. Paediatr."},{"key":"ref_22","first-page":"268","article-title":"Cancer in Africa","volume":"4","author":"Parkin","year":"2003","journal-title":"Epidemiol. Prev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pcl.2014.09.010","article-title":"Pediatric lymphomas and histiocytic disorders of childhood","volume":"62","author":"Allen","year":"2015","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00383-011-2982-5","article-title":"Intussusception as a presenting feature of Burkitt lymphoma: Implications for management and outcome","volume":"28","author":"England","year":"2012","journal-title":"Pediatr. Surg. Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jpedsurg.2007.01.033","article-title":"Clinical implications and surgical management of intussusception in pediatric patients with Burkitt lymphoma","volume":"42","author":"Gupta","year":"2007","journal-title":"J. Pediatr. Surg."},{"key":"ref_26","unstructured":"Padala, S.A., and Kallam, A. (2022). Diffuse Large B Cell Lymphoma. StatPearls, StatPearls Publishing."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-03-0973","article-title":"The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: A report of the BFM Group Study NHL-BFM95","volume":"105","author":"Woessmann","year":"2005","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00277-014-2271-1","article-title":"Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy","volume":"94","author":"Rovira","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.14694\/EdBook_AM.2015.35.e449","article-title":"ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?","volume":"35","author":"Nowakowski","year":"2015","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/leu.2011.378","article-title":"BCL2 mutations in diffuse large B-cell lymphoma","volume":"26","author":"Schuetz","year":"2012","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/pbc.21619","article-title":"Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group","volume":"51","author":"Miles","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.3324\/haematol.2020.253591","article-title":"BCL2 dependency in diffuse large B-cell lymphoma: It\u2019s a family affair","volume":"105","author":"Matulis","year":"2020","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2005-10-4213","article-title":"Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: A clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-M\u00fcnster) Multicenter Trial","volume":"107","author":"Oschlies","year":"2006","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2012-04-422709","article-title":"Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB\/LMB96 mature B-NHL therapy","volume":"121","author":"Gerrard","year":"2013","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11899-014-0219-0","article-title":"Primary mediastinal large B-cell lymphoma","volume":"9","author":"Walewski","year":"2014","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/pbc.21821","article-title":"Primary mediastinal B-cell lymphoma in the pediatric patient: Can a rational approach to therapy be based on adult studies?","volume":"52","author":"Attias","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3324\/haematol.2010.030809","article-title":"Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children","volume":"96","author":"Oschlies","year":"2011","journal-title":"Haematologica"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2011-05-326538","article-title":"The molecular pathogenesis of primary mediastinal large B-cell lymphoma","volume":"118","author":"Steidl","year":"2011","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0046-8177(99)90273-3","article-title":"Mediastinal B-cell lymphoma: A study of its histomorphologic spectrum based on 109 cases","volume":"30","author":"Paulli","year":"1999","journal-title":"Hum. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2141.2008.06988.x","article-title":"Recent advances in the understanding and management of diffuse large B-cell lymphoma in children","volume":"142","author":"Reiter","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1182\/blood-2018-04-791566","article-title":"How I treat primary mediastinal B-cell lymphoma","volume":"132","year":"2018","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1097\/PAS.0000000000000473","article-title":"Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling","volume":"39","author":"Yuan","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1200\/JCO.2000.18.22.3845","article-title":"Large-Cell Lymphoma Arising in the Mediastinum in Children and Adolescents Is Associated with an Excellent Outcome: A Children\u2019s Cancer Group Report","volume":"18","author":"Lones","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Derebas, J., Panuciak, K., Margas, M., Zawitkowska, J., and Lejman, M. (2022). The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients. Cancers, 14.","DOI":"10.3390\/cancers14061569"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/bjh.15793","article-title":"Lymphoblastic lymphoma in children and adolescents: Review of current challenges and future opportunities","volume":"185","author":"Burkhardt","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2005.05735.x","article-title":"The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence","volume":"131","author":"Burkhardt","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bjh.12042","article-title":"The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: A Children\u2019s Oncology Group report","volume":"159","author":"Patel","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2009.08006.x","article-title":"Paediatric lymphoblastic T-cell leukaemia and lymphoma: One or two diseases?","volume":"149","author":"Burkhardt","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/leu.2015.203","article-title":"Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia","volume":"30","author":"Balbach","year":"2016","journal-title":"Leukemia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2012-05-429514","article-title":"Pediatric-type nodal follicular lymphoma: An indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement","volume":"120","author":"Louissaint","year":"2012","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1046\/j.1365-2141.1998.00941.x","article-title":"Conservative management of follicular non-Hodgkin\u2019s lymphoma in childhood","volume":"103","author":"Atra","year":"1998","journal-title":"Br. J. Haematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3324\/haematol.2009.013177","article-title":"Pediatric follicular lymphoma\u2014A clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin\u2019s Lymphoma\u2014Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials","volume":"95","author":"Oschlies","year":"2010","journal-title":"Haematologica"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/pbc.23152","article-title":"Pediatric indolent lymphoma\u2014Would less be better?","volume":"57","author":"Perkins","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.hoc.2008.07.013","article-title":"Follicular Lymphoma: Clinical Features and Treatment","volume":"22","author":"Tan","year":"2008","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_55","unstructured":"Kaseb, H., Mukkamalla, S.K.R., and Rajasurya, V. (2022). Anaplastic Large Cell Lymphoma. StatPearls, StatPearls Publishing."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/bjh.13958","article-title":"Anaplastic large cell lymphoma in paediatric and young adult patients","volume":"173","author":"Turner","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1182\/blood.V91.6.2076","article-title":"ALK-Positive Lymphoma: A Single Disease with a Broad Spectrum of Morphology","volume":"91","author":"Benharroch","year":"1998","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood-2007-07-100958","article-title":"Prognostic factors in childhood anaplastic large cell lymphoma: Results of a large European intergroup study","volume":"111","author":"Reiter","year":"2008","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MPH.0b013e3182431e02","article-title":"Plasma Cytokine Profiles at Diagnosis in Pediatric Patients with Non-Hodgkin Lymphoma","volume":"34","author":"Mellgren","year":"2012","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/bjh.13265","article-title":"Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas","volume":"168","author":"Boi","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/sj.leu.2403888","article-title":"Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma","volume":"19","author":"Mussolin","year":"2005","journal-title":"Leukemia"},{"key":"ref_62","unstructured":"(2021, December 18). National Cancer Institute Childhood Non-Hodgkin Lymphoma Treatment (PDQ\u00ae)\u2014Health Professional Version, Available online: https:\/\/www.cancer.gov\/types\/lymphoma\/hp\/child-nhl-treatment-pdq#cit\/section_6.21."},{"key":"ref_63","unstructured":"Stuart, H., Orkin, D.E.F., Thomas, L.A., Samuel, E., Lux, D.G., and Nathan, D.G. (2015). Pathologic Features: Diffuse Large B-Cell Lymphomas. Nathan and Oski\u2019s Hematology and Oncology of Infancy and Childhood, Elsevier Health Sciences. [8th ed.]."},{"key":"ref_64","first-page":"113","article-title":"Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma","volume":"13","author":"Cairo","year":"2015","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2014.59.5827","article-title":"Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead","volume":"33","author":"Reiter","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1200\/JCO.1994.12.5.899","article-title":"Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: A prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies","volume":"12","author":"Reiter","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1002\/pbc.25187","article-title":"Advanced stage anaplastic large cell lymphoma in children and adolescents: Results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: A report from the children\u2019s oncology group","volume":"61","author":"Alexander","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood.V97.12.3699","article-title":"Short-pulse B\u2013non-Hodgkin lymphoma\u2013type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: A report of the Berlin-Frankfurt-M\u00fcnster Group Trial NHL-BFM 90","volume":"97","author":"Seidemann","year":"2001","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1182\/blood-2018-99-113481","article-title":"Children\u2019s Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL)","volume":"132","author":"Hayashi","year":"2018","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1080\/10428190802517732","article-title":"Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia","volume":"49","author":"Chang","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1002\/cncr.28930","article-title":"Augmented Berlin-Frankfurt-M\u00fcnster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)","volume":"120","author":"Rytting","year":"2014","journal-title":"Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1200\/JCO.20.00256","article-title":"Children\u2019s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_73","unstructured":"Swerdlow, S., Campo, E., Harris, N., Jaffe, E., Pileri, S., Stein, H., Thiele, J., Arber, D., Hasserjian, R., and Le Beau, M. (2017). WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, Revised, IARC. [4th ed.]."},{"key":"ref_74","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., and Vardiman, J.W. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e27770","DOI":"10.1002\/pbc.27770","article-title":"IRF4 translocation status in pediatric follicular and diffuse large B-cell lymphoma patients enrolled in Children\u2019s Oncology Group trials","volume":"66","author":"Chisholm","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: It is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte","year":"2006","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for High-Risk, Mature B-Cell Non-Hodgkin\u2019s Lymphoma in Children","volume":"382","author":"Pillon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.14951","article-title":"Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R","volume":"179","author":"Chen","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1200\/JCO.21.00920","article-title":"Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide with Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents with Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial","volume":"39","author":"Burke","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1200\/JCO.2003.08.151","article-title":"Primary Mediastinal Large B-Cell Lymphoma with Sclerosis in Pediatric and Adolescent Patients: Treatment and Results From Three Therapeutic Studies of the Berlin-Frankfurt-M\u00fcnster Group","volume":"21","author":"Seidemann","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Prokoph, N., Larose, H., Lim, M.S., Burke, G.A.A., and Turner, S.D. (2018). Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond. Cancers, 10.","DOI":"10.3390\/cancers10040099"},{"key":"ref_82","first-page":"3591","article-title":"CD30+ Anaplastic Large-Cell Lymphoma in Children: Analysis of 82 Patients Enrolled in Two Consecutive Studies of the French Society of Pediatric Oncology","volume":"92","author":"Deley","year":"1998","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.1200\/jco.2010.28.15_suppl.9511","article-title":"Advanced-stage anaplastic large-cell lymphoma in children and adolescents: Results of ANHL0131, a randomized phase III trial with standard APO (doxorubicin, prednisone, vincristine) versus consolidation with a regimen including vinblastine: A report from the Children\u2019s Oncology Group","volume":"28","author":"Kraveka","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_84","first-page":"416","article-title":"Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: A BFM group report","volume":"95","author":"Reiter","year":"2000","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood.2019001557","article-title":"How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children","volume":"135","author":"Teachey","year":"2020","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/pbc.23110","article-title":"Rituximab in combination with multiagent chemotherapy for pediatric follicular lymphoma","volume":"57","author":"Kumar","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/bjh.16461","article-title":"Treatment of relapsed\/refractory paediatric aggressive B-cell non-Hodgkin lymphoma","volume":"189","author":"Moleti","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3324\/haematol.2014.121434","article-title":"Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective \u201cLymphomes Malins B\u201d protocols. A Soci\u00e9t\u00e9 Fran\u00e7aise des Cancers de l\u2019Enfant study","volume":"100","author":"Jourdain","year":"2015","journal-title":"Haematologica"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Burkhardt, B., Taj, M., Garnier, N., Minard-Colin, V., Hazar, V., Mellgren, K., Osumi, T., Fedorova, A., Myakova, N., and Verdu-Amoros, J. (2021). Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations. Cancers, 13.","DOI":"10.3390\/cancers13092075"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e27873","DOI":"10.1002\/pbc.27873","article-title":"Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study","volume":"66","author":"Rigaud","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"17949","DOI":"10.1002\/pbc.26105","article-title":"Relapsed\/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia\/Lymphoma Study Group","volume":"63","author":"Osumi","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pbc.21753","article-title":"A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent\/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: A report from the Children\u2019s Oncology Group","volume":"52","author":"Griffin","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbmt.2009.09.021","article-title":"Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents","volume":"16","author":"Gross","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/pbc.24722","article-title":"Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation","volume":"60","author":"Ricafort","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/bmt.2015.57","article-title":"Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: A study on behalf of the SFCE and SFGM-TC","volume":"50","author":"Strullu","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/A:1008352726155","article-title":"Relapses of childhood anaplastic large-cell lymphoma: Treatment results in a series of 41 children\u2014A report from the French Society of Pediatric Oncology","volume":"11","author":"Quartier","year":"2000","journal-title":"Ann. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1182\/bloodadvances.2018026203","article-title":"Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients","volume":"3","author":"Naik","year":"2019","journal-title":"Blood Adv."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/bjh.15764","article-title":"Childhood, adolescent and young adult non-Hodgkin lymphoma: Current perspectives","volume":"185","author":"Cairo","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1705008","article-title":"The graft-versus-lymphoma effect: Clinical review and future opportunities","volume":"36","author":"Butcher","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1080\/10428190310001623694","article-title":"Graft-vs.-lymphoma effect in various histologies of non-Hodgkin\u2019s lymphoma","volume":"44","author":"Maloney","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/annonc\/mdn404","article-title":"Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation","volume":"19","author":"Bishop","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00277-019-03714-x","article-title":"Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin\u2019s lymphoma","volume":"98","author":"Jeon","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2012.45.0247","article-title":"Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation","volume":"31","author":"Storb","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.6004\/jnccn.2020.7608","article-title":"Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma","volume":"18","author":"Pommert","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_105","unstructured":"Genentech Inc. (2021, December 30). RITUXAN\u00ae (Rituxan) [Package Insert]. U.S. Food and Drug Administration Website, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103705s5467lbl.pdf."},{"key":"ref_106","unstructured":"Minard, V., and Gross, T. (2016). Results of the Randomized Intergroup Trial Inter-B-NHL Ritux 2010 for Children and Adolescents with High-Risk B-Cell Non-Hodgkin lymphoma (B-NHL) and Mature Acute Leukemia (B-AL): Evaluation of Rituximab (R) Efficacy in Addition to Standard LMB Chemotherapy (CT) Regimen, American Society of Clinical Oncology. Gustave Roussy, Cancer Campus, Grand Paris, Children\u2019s Oncology Group."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Barth, M.J., Goldman, S., Smith, L., Perkins, S.L., Shiramizu, B., Gross, T.G., Harrison, L., Sanger, W., Geyer, M.B., and Giulino, L.B. (2013). Rituximab Pharmacokinetics in Children and Adolescents with de Novo Intermediate and Advanced mature B-Cell Lymphoma\/Leukemia: A Children\u2019s Oncology Group (COG) Report, American Society of Clinical Oncology.","DOI":"10.1200\/jco.2013.31.15_suppl.3055"},{"key":"ref_108","unstructured":"Seattle Genetics Inc. (2021, December 30). ADCETRIS\u00ae (Brentuximab Vedotin) [Package Insert]. U.S. Food and Drug Administration Website, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125388s097lbl.pdf."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood.2020009806","article-title":"Brentuximab Vedotin in Combination with Chemotherapy for Pediatric Patients with ALK+ ALCL: Results of COG Trial ANHL12P1","volume":"137","author":"Lowe","year":"2021","journal-title":"Blood"},{"key":"ref_110","unstructured":"Shustov, A. (2019). Ceritinib with Brentuximab Vedotin in Treating Patients with ALK-Positive Anaplastic Large Cell Lymphoma, Last updated October 2019."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab Combined with Brentuximab Vedotin for Relapsed\/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_112","unstructured":"Brugieres, L. (2021). Nivolumab for Pediatric and Adult Relapsing\/Refractory ALK+, for Evaluation of Response in Patients with Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission after Relapse (Cohort 2), Gustave Roussy, Cancer Campus. Last updated July 2021."},{"key":"ref_113","unstructured":"Amgen Inc (2021, December 30). BLINCYTO\u00ae (Blinatumomab) [Package Insert]. U.S. Food and Drug Administration Website, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125557s013lbl.pdf."},{"key":"ref_114","unstructured":"Bargou, R. (2015). Safety Study of the Bispecific T-Cell Engager Blinatumomab (MT103) in Patients with Relapsed NHL, Amgen Research (Munich) GmbH. Last updated January 2015."},{"key":"ref_115","unstructured":"Amgen Research (Munich) Gmb (2017). Clinical Study with Blinatumomab in Patients with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Amgen Research (Munich) GmbH. Last Updated January 2017."},{"key":"ref_116","unstructured":"Breese, E. (2021). Pembro + Blina Combination in Pediatric and Young Adult Patients with Relapsed\/Refractory Acute Leukemia or Lymphoma, Children\u2019s Hospital Medical Center. Last updated April 2021."},{"key":"ref_117","unstructured":"Inaba, H. (2021). Total Therapy XVII for Newly Diagnosed Patients with Acute Lymphoblastic Leukemia and Lymphoma, St. Jude Children\u2019s Research Hospital. Last updated August 2021."},{"key":"ref_118","unstructured":"Wyeth Pharmaceuticals Inc., and Subsidiary of Pfizer Inc. (2021, December 30). BESPONSA\u2122 (Inotuzumab Ozogamicin) [Package Insert]. U.S. Food and Drug Administration Website, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761040s000lbl.pdf."},{"key":"ref_119","unstructured":"O\u2019Brien, M.M. (2016). Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia, Children\u2019s Oncology Group. Last updated December 2016."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41375-022-01576-3","article-title":"Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: Results from a phase II trial","volume":"36","author":"Pennesi","year":"2022","journal-title":"Leukemia"},{"key":"ref_121","unstructured":"(2021, December 30). GlaxoSmithKline, ARRANON\u00ae (Nelarabine) [Package Insert]. U.S. Food and Drug Administration Website, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021877s009lbl.pdf."},{"key":"ref_122","unstructured":"Winter, S.S. (2021). Combination Chemotherapy in Treating Young Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma, National Cancer Institute (NCI). Last updated September 2021."},{"key":"ref_123","unstructured":"Novartis Pharmaceuticals Corporation (2021, December 30). KYMRIAH\u00ae (Tisagenlecleucel) [Package Insert]. U.S. Food and Drug Administration Website, Available online: https:\/\/www.fda.gov\/media\/107296\/download."},{"key":"ref_124","unstructured":"National Library of Medicine (U.S.) (2021, December 28). (August 1, 2018) Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients. Identifier: NCT03610724, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03610724."},{"key":"ref_125","unstructured":"Kite Pharma Inc (2021, December 30). YESCARTA\u00ae (Axicabtagene Ciloleucel) [Package Insert]. U.S. Food and Drug Administration Website, Available online: https:\/\/www.fda.gov\/media\/108377\/download."},{"key":"ref_126","unstructured":"National Library of Medicine (U.S.) (2021, December 28). (December 9, 2015) Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants with Relapsed\/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma. Identifier: NCT02625480, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02625480."},{"key":"ref_127","unstructured":"Shah, N.N. (2021). Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-Expressing B Cell Malignancies, Last updated December 2021."},{"key":"ref_128","unstructured":"Schultz, L. (2021). CD22-CAR T Cells in Children and Young Adults with B Cell Malignancies, Stanford University. Last updated May 2021."},{"key":"ref_129","unstructured":"Shah, N.N. (2021). CD19\/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19\/CD22-expressing B Cell Malignancies, Last updated December 2021."},{"key":"ref_130","unstructured":"Heslop, H.E. (2020). LMP-Specific T-Cells for Patients with Relapsed EBV-Positive Lymphoma, Baylor College of Medicine, The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine. Last updated July 2020."},{"key":"ref_131","unstructured":"Hu, Y. (2021). Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies, Wuhan Union Hospital. Last updated April 2021."},{"key":"ref_132","unstructured":"Nieto, Y.L. (2021). Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients with Recurrent or Refractory B-Cell Non-Hodgkin\u2019s Lymphoma, Last updated January 2017."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2014.200","article-title":"Adoptive therapy with donor lymphocyte infusion after allogenic hematopoietic SCT in pediatric patients","volume":"50","author":"Gozdzik","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_134","unstructured":"Merck Sharp & Dohme Corp. (2021, December 30). A Subsidiary of Merck & Co. Inc. KEYTRUDA\u00ae (Pembrolizumab) [Package Insert]. U.S. Food and Drug Administration Website, Available online: https:\/\/www.fda.gov\/media\/108377\/download."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(19)30671-0","article-title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): Interim analysis of an open-label, single-arm, phase 1-2 trial","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_136","unstructured":"Bristol-Myers Squibb Company (2021, December 30). OPDIVO (Nivolumab) [Package Insert]. U.S. Food and Drug Administration Website, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125554s090lbl.pdf."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","article-title":"Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): A multicentre, open-label, single-arm, phase 1\u20132 trial","volume":"21","author":"Davis","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_138","unstructured":"Bristol-Myers, S. (2020). A Study of Nivolumab Plus Brentuximab Vedotin in Patients between 5 and 30 Years Old, with Hodgkin\u2019s Lymphoma (cHL), Relapsed or Refractory from First Line Treatment. CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation), Seagen Inc.. Last updated June 2020."},{"key":"ref_139","unstructured":"Genentech Inc (2021, December 30). TECENTRIQ\u00ae (Atezolizumab) [Package Insert]. U.S. Food and Drug Administration Website, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761034s042lbl.pdf."},{"key":"ref_140","unstructured":"National Library of Medicine (U.S.) (2021, December 29). (September 4, 2015) A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 PD-L1 Antibody) in Pediatric and Young Adult Participants with Solid Tumors. Identifier: NCT02541604, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02541604."},{"key":"ref_141","unstructured":"Pfizer Inc (2021, December 01). XALKORI\u00ae (Crizotinib) [Package Insert]. U.S. Food and Drug Administration Website, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/202570s030lbl.pdf."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: A Children\u2019s Oncology Group phase 1 consortium study","volume":"14","author":"Lim","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00277-015-2501-1","article-title":"Effect of rituximab on adult Burkitt\u2019s lymphoma: A systematic review and meta-analysis","volume":"95","author":"Nie","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2012.255","article-title":"Rituximab and FAB\/LMB 96 chemotherapy in children with Stage III\/IV B-cell non-Hodgkin lymphoma: A Children\u2019s Oncology Group report","volume":"27","author":"Goldman","year":"2013","journal-title":"Leukemia"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/bjh.15520","article-title":"Excellent outcomes in children and adolescents with CNS(+) Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: Results from FAB\/LMB96 and COG ANHL01P1","volume":"185","author":"Frazer","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.13040","article-title":"Rituximab with chemotherapy in children and adolescents with central nervous system and\/or bone marrow-positive Burkitt lymphoma\/leukaemia: A Children\u2019s Oncology Group Report","volume":"167","author":"Goldman","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1182\/bloodadvances.2020001518","article-title":"Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis","volume":"4","author":"Tierens","year":"2020","journal-title":"Blood Adv."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1038\/s41375-021-01256-8","article-title":"A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma","volume":"35","author":"Goldman","year":"2021","journal-title":"Leukemia"},{"key":"ref_149","unstructured":"U.S. Food and Drug Administration (2021, December 30). FDA Approves Rituximab Plus Chemotherapy for Pediatric Cancer Indications, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-rituximab-plus-chemotherapy-pediatric-cancer-indications."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2016.11.009","article-title":"Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review","volume":"109","author":"Berger","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S2352-3026(18)30153-4","article-title":"Brentuximab vedotin for paediatric relapsed or refractory Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma: A multicentre, open-label, phase 1\/2 study","volume":"5","author":"Locatelli","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children with High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10555-019-09834-0","article-title":"Immunotherapy in pediatric acute lymphoblastic leukemia","volume":"38","author":"Inaba","year":"2019","journal-title":"Cancer Metastasis Rev."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","article-title":"Long-term outcome of patients with relapsed\/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab","volume":"3","author":"Dufner","year":"2019","journal-title":"Blood Adv."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1080\/10428194.2020.1759055","article-title":"Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"61","author":"Coyle","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","article-title":"Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"33","author":"Bhojwani","year":"2019","journal-title":"Leukemia"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bjh.14094","article-title":"A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy","volume":"174","author":"Goy","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","article-title":"Management of important adverse events associated with inotuzumab ozogamicin: Expert panel review","volume":"53","author":"Kebriaei","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Salvaris, R., Ong, J., and Gregory, G.P. (2021). Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas. J. Pers. Med., 11.","DOI":"10.3390\/jpm11050355"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Ghosh, N., Townsend, W., Dickinson, M., Topp, M.S., Tani, M., Santoro, A., Crump, M., Morschhauser, F., Le Gouill, S., and Mehta, A. (2021). Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed\/Refractory (R\/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study, American Society of Hematology Annual Meeting and Exposition.","DOI":"10.1182\/blood-2021-147780"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients with Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","volume":"40","author":"Budde","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1200\/JCO.2000.18.5.995","article-title":"Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies","volume":"18","author":"Kisor","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II Study of Nelarabine (compound 506U78) in Children and Young Adults with Refractory T-Cell Malignancies: A Report From the Children\u2019s Oncology Group","volume":"23","author":"Berg","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1634\/theoncologist.2006-0017","article-title":"FDA Drug Approval Summary: Nelarabine (Arranon\u00ae) for the Treatment of T-Cell Lymphoblastic Leukemia\/Lymphoma","volume":"13","author":"Cohen","year":"2008","journal-title":"Oncologist"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/JCO.20.00531","article-title":"Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children\u2019s Oncology Group AALL0434","volume":"38","author":"Hayashi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/bjh.14874","article-title":"Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: Results of a phase 4 study","volume":"179","author":"Zwaan","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17474086.2017.1262757","article-title":"Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma","volume":"10","author":"Kadia","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40364-021-00309-5","article-title":"Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma","volume":"9","author":"Yin","year":"2021","journal-title":"Biomark. Res."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma","volume":"386","author":"Bishop","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: The phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1182\/blood-2019-125753","article-title":"Early Response Observed in Pediatric Patients with Refractory\/Relapsed B-Cell Non-Hodgkin Lymphoma Treated with Sequential Chimeric Antigen Receptor T Cells","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"e22504","DOI":"10.1200\/JCO.2020.38.15_suppl.e22504","article-title":"Bianca: Phase II, single-arm, global trial to determine efficacy and safety of tisagenlecleucel in pediatric\/young adult (YA) patients (Pts) with relapsed\/refractory B-cell non-Hodgkin lymphoma (R\/R B-NHL)","volume":"38","author":"Minard","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1002\/acg2.54","article-title":"CAR-T cell Therapy for Non-Hodgkin Lymphomas: A New Treatment Paradigm","volume":"2","author":"Hill","year":"2019","journal-title":"Adv. Cell Gene Ther."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1111\/bjh.16761","article-title":"Primary mediastinal large B-cell lymphoma in paediatric and adolescent patients: Emerging questions in the era of immunotherapy","volume":"190","author":"Kohorst","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Bouchkouj, N., Zimmerman, M., Kasamon, Y.L., Wang, C., Dai, T., Xu, Z., Wang, X., Theoret, M., Purohit-Sheth, T., and George, B. (2022). FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma. Oncologist, 1\u20138.","DOI":"10.1093\/oncolo\/oyac054"},{"key":"ref_184","unstructured":"Rosa, K. (2022, February 21). FDA Approves Liso-Cel for Refractory Large B-Cell Lymphoma. Available online: https:\/\/www.onclive.com\/view\/fda-approves-liso-cel-for-refractory-large-b-cell-lymphoma."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13045-020-01011-z","article-title":"New agents and regimens for diffuse large B cell lymphoma","volume":"13","author":"Wang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-137233","article-title":"ZUMA-4: A Phase 1\/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients with Relapsed\/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma","volume":"136","author":"Wayne","year":"2020","journal-title":"Blood"},{"key":"ref_187","unstructured":"Wayne, A.S., Huynh, V., Hijiya, N., Rouce, R., Brown, P.A., Krueger, J., Kitko, C.L., Ziga, E.D., Hermiston, M.L., and Richards, M.K. (2021, January 11). ZUMA-4 Phase 1 Long-Term Results: KTE-X19 Chimeric Antigen Receptor T-Cell Therapy in Pediatric\/Adolescent Patients with Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia. Proceedings of the European Hematology Association Annual Meeting 2021, Virtual. Available online: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.27989."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood.2020009432","article-title":"CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR\u2013refractory large B-cell lymphoma","volume":"137","author":"Baird","year":"2021","journal-title":"Blood"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-143239","article-title":"CD19\/CD22 Dual-Targeted Chimeric Antigen Receptor T-Cell Therapy for Relapsed\/Refractory Aggressive B-Cell Lymphoma: A Safety and Efficacy Study","volume":"136","author":"Hu","year":"2020","journal-title":"Blood"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: A phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat. Med."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","article-title":"Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Dom\u00ednguez, D.J., Hontecillas-Prieto, L., Palaz\u00f3n-Carri\u00f3n, N., Jim\u00e9nez-Cortegana, C., S\u00e1nchez-Margalet, V., and de la Cruz-Merino, L. (2022). Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics. Cancers, 14.","DOI":"10.3390\/cancers14061469"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1053\/j.seminoncol.2014.12.030","article-title":"Epstein-Barr Virus\u2013Associated Lymphomas","volume":"42","author":"Grywalska","year":"2015","journal-title":"Semin. Oncol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13045-020-00996-x","article-title":"Natural killer cell-based immunotherapy for acute myeloid leukemia","volume":"13","author":"Xu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_198","unstructured":"Nato, Y., Banerjee, P., Kaur , I., Thall, P., Hosing, C., Srour, S.A., Griffin, L., Barnett, M., Champlin , R.E., and Shpall, E.J. Immunotherapy with ex vivo-expanded cord blood (CB)-derived nk cells combined with high-dose chemotherapy (HDC) and autologous stem cell transplant (ASCT) for B-cell non-hodgkin\u2019s lymphoma (NHL). Proceedings of the Transplant & Cellular Therapy Meetings, Available online: https:\/\/tct.confex.com\/tct\/2021\/meetingapp.cgi\/Paper\/18012."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1182\/blood-2018-99-113906","article-title":"Donor Lymphocyte Infusions for the Treatment of Relapsed Non-Hodgkin Lymphoma Following Allogeneic Stem Cell Transplantation: A LWP-EBMT Study","volume":"132","author":"Robinson","year":"2018","journal-title":"Blood"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"690499","DOI":"10.3389\/fimmu.2021.690499","article-title":"Cell Therapy with TILs: Training and Taming T Cells to Fight Cancer","volume":"12","author":"Kumar","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of Patients with Metastatic Melanoma with Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2","volume":"86","author":"Rosenberg","year":"1994","journal-title":"JNCI J. Nat. Cancer Inst."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"v363","DOI":"10.1093\/annonc\/mdx373.023","article-title":"Phenotypic and functional characterization of tumor infiltrating lymphocytes (TIL) grown from non-hodgkin lymphoma tumors: Implications for the development of novel therapies for lymphoma","volume":"28","author":"Karyampudi","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"2040620719841591","DOI":"10.1177\/2040620719841591","article-title":"The role of pembrolizumab in relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"10","author":"Tomassetti","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for Relapsed\/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study","volume":"37","author":"Ansell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(19)30693-X","article-title":"Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): A multicentre phase 1\u20132 study","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting ALK with Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children\u2019s Oncology Group Study","volume":"35","author":"Voss","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_211","unstructured":"(2022, February 16). Pfizer\u2019s Xalkori (Crizotinib) Approved by FDA for ALK-Positive Anaplastic Large Cell Lymphoma in Children and Young Adults [News Release]. Pfizer. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-xalkorir-crizotinib-approved-fda-alk-positive."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1158\/1078-0432.CCR-13-3007","article-title":"Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo","volume":"20","author":"Hao","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Kim, S.J., Yoon, D.H., Kang, H.J., Hong, J.Y., Lee, H.S., Oh, S.Y., Shin, H.-J., Kong, J.H., Yi, J.H., and Sakamoto, K. (2019). Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6303-z"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/12\/2912\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:30:33Z","timestamp":1760139033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/12\/2912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":213,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["cancers14122912"],"URL":"https:\/\/doi.org\/10.3390\/cancers14122912","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]}}}